CRISPR stocks sank on news the gene editing tool can veer off target. But that’s hardly news – STAT

Posted: June 1, 2017 at 10:44 am

The Cuban hustle: Doctors drive cabs and work abroad

The Cuban hustle: Doctors drive cabs and work abroad to make up for meager pay

Dope Sick: A harrowing story of best friends, addiction

Dope Sick: A harrowing story of best friends, addiction and a stealth killer

Is colonoscopy the gold standard for colorectal cancer screening?

Is colonoscopy the gold standard for colorectal cancer screening?

Big pension funds seek to unseat Mylan directors over

Big pension funds seek to unseat Mylan directors over executive pay

Amgen sues the FDA for denying its right to

Amgen sues the FDA for denying its right to use a key marketing incentive

Pharmalot, Pharmalittle: California transparency bill moves closer to becoming

Pharmalot, Pharmalittle: California transparency bill moves closer to becoming law

More here:

CRISPR stocks sank on news the gene editing tool can veer off target. But that's hardly news - STAT

Related Posts

Comments are closed.

Archives